Janus Kinase Inhibitor, Tofacitinib, in Refractory Juvenile Dermatomyositis: a Retrospective Multi-Central Study in China

Junmei Zhang,Li Sun,XinWei Shi,Shipeng Li,Cuihua Liu,Xiaoqing Li,Meiping Lu,Jianghong Deng,Xiaohua Tan,Wanzhen Guan,Guomin Li,Xinran Wen,Ping Liu,Caifeng Li
DOI: https://doi.org/10.1186/s13075-023-03170-z
2023-01-01
Arthritis Research & Therapy
Abstract:Juvenile dermatomyositis (JDM) is a chronic autoimmune disease. Some patients remain in an active state even though they were administrated with a combination of corticosteroid and methotrexate. Existing research has suggested that interferon and Janus kinase played an important role in pathogenesis. Existing research has suggested the efficacy of JAK inhibitors (JAKi). Our retrospective study aimed to investigate the efficacy of tofacitinib in refractory JDM patients. A total of eighty-eight patients in China who had been diagnosed with JDM and subjected to tofacitinib therapy for over 3 months were retrospectively analyzed. Skin and muscle manifestations were assessed using the Cutaneous Assessment Tool-binary method (CAT-BM), Childhood Myositis Assessment Scale (CMAS), and kinase. Pulmonary function was assessed using a high-resolution CT (computerized tomography) scan and pulmonary symptoms. All patients were subjected to regular follow-up, and core measures were assessed every 3 months after initiation. Furthermore, the data were analyzed using the Wilcoxon single test, Mann–Whitney U test, and chi-square test. Compared with the baseline data, skin and muscle manifestations were found significantly improved during the respective follow-up visit. At the most recent follow-up, nearly 50
What problem does this paper attempt to address?